Atypical pathogen infection in community-acquired pneumonia

被引:34
|
作者
Yu, Yun [1 ]
Fei, Aihua [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Emergency, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China
关键词
Atypical pathogen; community-acquired pneumonia (CAP); macrolide-resistant; empirical atypical coverage; RESISTANT MYCOPLASMA-PNEUMONIAE; INCREASED MACROLIDE RESISTANCE; REAL-TIME PCR; CHLAMYDIA-PNEUMONIAE; LUNG-CANCER; HOSPITALIZED-PATIENTS; ADULT PATIENTS; ETIOLOGY; GUIDELINES; MANAGEMENT;
D O I
10.5582/bst.2016.01021
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Community-acquired pneumonia (CAP) is a world wide cause of morbidity and mortality. The etiology of CAP is different between countries and changes over time. With the increasing incidence, atypical pathogens are attracting more and more attention all over the world. In many countries, atypical pathogens are one of the main pathogens of CAP, and even could be the most prevalent etiology in China. Atypical pathogen infections can cause multi-system complications, which leads to a worse prognosis. Although still controversial, empirical antibiotic coverage of atypical pathogens in CAP may improve outcomes, shorten length of hospitalization, reduce mortality and lower total hospitalization costs. The macrolide resistance rate of atypical pathogens, especially Mycoplasma Pneumoniae (M. Pneumoniae) is high, so fluoroquinolones or tetracyclines should be considered as alternative therapy.
引用
收藏
页码:7 / 13
页数:7
相关论文
共 50 条
  • [41] Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia
    Lui, Grace
    Ip, Margaret
    Lee, Nelson
    Rainer, Timothy H.
    Man, Shin Y.
    Cockram, Clive S.
    Antonio, Gregory E.
    Ng, Margaret H. L.
    Chan, Michael H. M.
    Chau, Shirley S. L.
    Mak, Paulina
    Chan, Paul K. S.
    Ahuja, Anil T.
    Sung, Joseph J. Y.
    Hui, David S. C.
    RESPIROLOGY, 2009, 14 (08) : 1098 - 1105
  • [42] Community-acquired pneumonia
    Kolditz, M.
    Hoeffken, G.
    PNEUMOLOGE, 2009, 6 (03): : 179 - 190
  • [43] Community-Acquired Pneumonia
    Rider, Ashley C.
    Frazee, Bradley W.
    EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 2018, 36 (04) : 665 - +
  • [44] Community-acquired pneumonia
    Jose, Ricardo J.
    Periselneris, Jimstan N.
    Brown, Jeremy S.
    CURRENT OPINION IN PULMONARY MEDICINE, 2015, 21 (03) : 212 - 218
  • [45] Community-acquired pneumonia
    Prina, Elena
    Ranzani, Otavio T.
    Torres, Antoni
    LANCET, 2015, 386 (9998) : 1097 - 1108
  • [46] Community-acquired pneumonia
    Remington, Leah T.
    Sligl, Wendy I.
    CURRENT OPINION IN PULMONARY MEDICINE, 2014, 20 (03) : 215 - 224
  • [47] Community-acquired pneumonia
    Carbonara, Sergio
    Monno, Laura
    Longo, Benedetta
    Angarano, Gioacchino
    CURRENT OPINION IN PULMONARY MEDICINE, 2009, 15 (03) : 261 - 273
  • [48] Community-acquired pneumonia
    Polverino, E.
    Marti, A. Torres
    MINERVA ANESTESIOLOGICA, 2011, 77 (02) : 196 - 211
  • [49] Distribution of the atypical pathogens of community-acquired pneumonia to disease severity
    Gong, Cheng
    Zhang, Tiegaug
    Luo, Ming
    Li, Aihua
    Doug, Mei
    Li, Maozhong
    Wang, Yiting
    Huang, Fang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (11) : 5991 - +
  • [50] Delafloxacin as a treatment option for community-acquired pneumonia infection
    Nascimento-Carvalho, Cristiana M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (15) : 1975 - 1982